Source: GlobalNewswire

Press Release: Zosano Pharma : Zosano Pharma Presents Early-Onset of Action Data for Qtrypta in Acute Treatment of Migraines

FREMONT, Calif., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that early onset of action data for Qtrypta , Zosano's investigational therapy for the acute treatment of migraine formulated utilizing its microneedle system, were presented at the Annual Headache Cooperative of the Pacific Winter Conference.

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Annual Revenue
$ < 1M
Steven Lo's photo - President & CEO of Zosano Pharma

President & CEO

Steven Lo

CEO Approval Rating


Read more